Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

High Blood Pressure: A Side Effect of Drugs, Poisons, and Food

High Blood Pressure: A Side Effect of Drugs, Poisons, and Food Abstract A variety of therapeutic agents or chemical substances can induce either a transient or a sustained increase in blood pressure. These agents increase arterial pressure by either causing sodium retention and extracellular volume expansion or directly or indirectly activating the sympathetic nervous system. Some agents act directly on arteriolar smooth muscle. For certain agents, the mechanism of pressure elevation is mixed or unknown. Paradoxically, some agents that are used to lower arterial pressure may acutely increase arterial pressure. Also, a rebound increase in pressure may be encountered after discontinuation of certain antihypertensive agents. In general, these chemically induced increases in arterial pressure are small and transient; however, severe hypertension involving encephalopathy, stroke, and irreversible renal failure has been reported. Careful evaluation of a patient's drug regimen may identify chemically induced hypertension and prevent the need for evaluation and therapy. This study reviews the therapeutic agents or chemical substances that elevate blood pressure and their mechanisms of action. (Arch Intern Med. 1995;155:450-460) References 1. Messerli FH, Frohlich ED. High blood pressure: a common side effect of drugs, poisons and foods. Arch Intern Med . 1979;139:682-687.Crossref 2. Oren S, Grossman E, Messerli FH, Frohlich ED. High blood pressure: side effects of drugs, poisons, and food. Cardiol Clin . 1988;6:467-474. 3. Whitworth JA. Adrenocorticotrophin and steroid-induced hypertension in humans. Kidney Int . 1992;37( (suppl) ):34-37. 4. Whiteworth JA. Mechanisms of glucocorticoidinduced hypertension. Kidney Int . 1987;31: 1213-1224.Crossref 5. Sudhir K, Jennings GL, Esler MD, et al. Hydrocortisone-induced hypertension in humans: pressor responsiveness and sympathetic function. Hypertension . 1989:13:416-421.Crossref 6. Scoggins BA, Coghlan JP, Denton DA, et al. How do adrenocortical steroid hormones produce hypertension? Clin Exp Hypertens . 1984;6:315-328.Crossref 7. Whitworth JA, Gordon D, Andrews J, Scoggins BA. The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. J Hypertens . 1989;7:537-549.Crossref 8. Coghlan JP, Reid AF, Spence CD, Scoggins BA, Whitworth JA. Receptors and steroid-dependent hypertension. Clin Exp Pharmacol Physiol . 1988;15:163-172.Crossref 9. Sanders BP, Portman RJ, Ramey RA, Hill M, Strunk RC. Hypertension during reduction of long-term steroid therapy in young subjects with asthma. J Allergy Clin Immunol . 1992;89:816-821.Crossref 10. Beretta-Picolli C, Salvadore G, Crivelli GSPL, Weidmann P. Body-sodium and blood volume in a patient with licorice-induced hypertension. J Hypertens . 1985:3:19-23.Crossref 11. Horn B. Raritäten in der hausärztlichen praxis: Folgerungen für die aus- und weiterbildung (Rarities in the General Practice). Schweiz Rundsch Med Prax . 1986;75:1323-1327. 12. Leal-Cerro A, Garcia-Luna PP, Villar J, et al. Arterial hypertension as a complication of prolonged ketoconazole treatment. J Hypertens . 1989;7( (suppl) ):S212-213.Crossref 13. Marin F, Gonzalez Quintela A, Moya M, Suarez E, de Zarraga M. Pseudohyperaldosteronism due to application of an antihemorrhoid cream. Nephron . 1989:52:281-282.Crossref 14. Bartorelli A, Rimondini A. Severe hypertension in childhood due to prolonged skin application of a mineralocorticoid ointment. Hypertension . 1984:6:586-588.Crossref 15. Mantero F, Armanini D, Opocher G, et al. Mineralocorticoid hypertension due to a nasal spray containing 9 α-fluoroprednisolone. Am J Med . 1981;71:352-357.Crossref 16. Woods JW. Oral contraceptives and hypertension. Hypertension . 1988;11( (3) pt 2):11-15.Crossref 17. Tyson JE. Oral contraception and elevated blood pressure. Am Obstet Gynecol . 1968;100:875-877. 18. Saruta T. Saade GA, Kaplan NM. A possible mechanism for hypertension induced by oral contraceptives: diminished feedback suppression of renin release. Arch Intern Med . 1970;126:621-626.Crossref 19. Clezy TM, Foy BN, Hodge RL, Lumbers ER. Oral contraceptives and hypertension: an epidemiological survey. Br Heart J . 1972;34:1238-1243.Crossref 20. Khaw KT, Peart WS. Blood pressure and contraceptive use. BMJ . 1982;285:403-407.Crossref 21. Kannel WB. Oral contraceptive hypertension and thromboembolism. Int J Gynaecol Obstet . 1978-1979;16:466-472. 22. Mashchak CA, Lobo RA. Estrogen replacement therapy and hypertension. J Reprod Med . 1985;30:805-810. 23. Okada Y, Ogihara T. Hyperreninemia and hypertension observed during Kaufmann therapy of patients with gonadal dysgenesis and hypopituitarism. Endocrinol Jpn . 1989;36:211-218.Crossref 24. Gembitskii EV, Portnoi AS, Begunov AV. Diagnosis and therapeutic correction of changes in the cardiovascular system of patients with prostatic cancer treated with estrogens. Klin Med Mosk . 1990;68:41-45. 25. Graham S, Kennedy M. Recent developments in the toxicology of anabolic steroids. Drug Safety . 1990;5:458-476.Crossref 26. Bretza JA, Novey HS, Vaziri ND, Warner AS. Hypertension: a complication of danazol therapy. Arch Intern Med . 1980;140:1379-1380.Crossref 27. El-Din AS, Mostafa SM. Severe hypertension during anaesthesia for dacryocystorhinostomy. Anaesthesia . 1985;40:787-789.Crossref 28. Broughton Pipkin F, Waldron BA. Ketamine hypertension and the renin-angiotensin system. Clin Exp Hypertens . 1983;5:875-883.Crossref 29. Murphy JL Jr. Hypertension and pulmonary oedema associated with ketamine administration in a patient with a history of substance abuse. Can J Anaesth . 1993;40:160-164.Crossref 30. Munro HM, Sleigh JW, Paxton LD. The cardiovascular response to ketamine: the effects of clonidine and lignocaine. Acta Anaesthesiol Scand . 1993;37:75-78.Crossref 31. Mark JB, Greenberg LM. Intraoperative awareness and hypertensive crisis during high-dose fentanyl-diazepam-oxygen anesthesia. Anesth Analg . 1983;62:698-700.Crossref 32. Kashtan HI, Heyneker TJ, Morell RC. Atypical response to scopolamine in a patient with type IV hereditary sensory and autonomic neuropathy. Anesthesiology . 1992;76:140-142.Crossref 33. Wasserberger J, Ordog GJ. Naloxone-induced hypertension in patients on clonidine. Ann Emerg Med . 1988:17:557.Crossref 34. Levin ER, Sharp B, Drayer Jl, Weber MA. Case report: severe hypertension induced by naloxone. Med Sci . 1985:290:70-72.Crossref 35. Reinhart S. An acute hypertensive response after intravenous use of a new pentazocine formulation. Ann Emerg Med . 1985;14:591-593.Crossref 36. Saken R, Kates GL, Miller K. Drug-induced hypertension in infancy. J Pediatr . 1979;95:1077-1079.Crossref 37. Wellwood M, Goresky GV. Systemic hypertension associated with topical administration of 2.5% phenylephrine HCI. Am J Ophthalmol . 1982; 93:369-370. 38. Lai YK. Adverse effect of intraoperative phenylephrine 10%: case report. Br J Ophthalmol . 1989;73:468-469.Crossref 39. Nelson ME, Andrzejowski AZ. Systemic hypertension in patients receiving dipivalyl adrenaline for glaucoma. BMJ . 1988:297:741-742.Crossref 40. Whelan TV. Propranolol, epinephrine, and accelerated hypertension during hemodialysis. Ann Intern Med . 1987;106:327.Crossref 41. Brummett RE. Warning to otolaryngologists using local anesthetics containing epinephrine. Acta Otolaryngol . 1984:110:561. 42. Mito RS, Yagiela JA. Hypertensive response to levonordefrin in a patient receiving propranolol: report of case. J Am Dent Assoc . 1988;116:55-57. 43. Mann SJ, Krakoff LR. Hypertensive crisis caused by hypoglycemia and propranolol. Arch Intern Med . 1984;144:2427-2428.Crossref 44. Ryan JR, La Corte W, Jain A, McMahon FG. Hypertension in hypoglycemic diabetes treated with beta adrenergic antagonists. Hypertension . 1985;7:443-446. 45. Pentel P. Toxicity of over-the-counter stimulants. JAMA . 1984;252:1898-1903.Crossref 46. Heyman SN, Mevorach D, Ghanem J. Hypertensive crisis from chronic intoxication with nasal decongestant and cough medications. DICP . 1991;25:1068-1070. 47. Mariani PJ. Pseudoephedrine-induced hypertensive emergency: treatment with labetalol. Am J Emerg Med . 1986;4:141-142.Crossref 48. Bernstein E, Diskant BM. Phenylpropanolamine: a potentially hazardous drug. Ann Emerg Med . 1982;11:311-315.Crossref 49. Howrie DL, Wolfson JH. Phenylpropanolamineinduced hypertensive seizures. J Pediatr . 1983; 102:143-145.Crossref 50. Lasange L. Phenylpropanolamine and blood pressure. JAMA . 1985;253:2491-2492.Crossref 51. Pentel PR, Asinger RW, Benowitz NL. Propranolol antagonism of phenylpropanolamine-induced hypertension. Clin Pharmacol Ther . 1985: 37:488-494.Crossref 52. Horowitz JD, Lang WJ, Howes LG, et al. Hypertensive responses induced by phenylpropanolamine in anorectic and decongestant preparations. Lancet . 1980;1:60-61.Crossref 53. Lake CR, Zaloga G, Clymer R, Quirk RM, Chernow B. A double dose of phenylpropanolamine causes transient hypertension. Am J Med . 1988;85:339-343.Crossref 54. Lake CR, Zaloga G, Bray J, Rosenberg D, Chernow B. Transient hypertension after two phenylpropanolamine diet aids and the effects of caffeine: a placebo-controlled follow-up study. Am J Med . 1989:86:427-432.Crossref 55. Morgan JP, Funderburk FR. Phenylpropanolamine and blood pressure: a review of prospective studies. Am J Clin Nutr . 1992;55 ( (suppl 1) ):206S-210S. 56. Lovallo WR, Pincomb GA, Sung BH, Everson SA, Passey RB, Wilson MF. Hypertension risk and caffeine's effect on cardiovascular activity during mental stress in young men. Health Psychol . 1991;10:236-243.Crossref 57. James JE. The influence of user status and anxious disposition on the hypertensive effects of caffeine. Int J Psychophysiol . 1990;10:171-179.Crossref 58. Greenstadt L, Yang L, Shapiro D. Caffeine, mental stress, and risk for hypertension: a crosscultural replication. Psychosom Med . 1988;50:15-22.Crossref 59. Acevedo AG, Smith JK. Adverse reaction to use of caffeine in ECT. Am J Psychiatry . 1988;145: 529-530. 60. Harrison WM. McGrath PJ, Stewart JW, Quitkin F. MAOIs and hypertensive crises: the role of OTC drugs. J Clin Psychiatry . 1989;50:64-65. 61. Roche H, Hyman G, Nahas G. Hypertension and intravenous antidopaminergic drugs. N Engl J Med . 1985;312:1125-1126.Crossref 62. Sheridan C, Chandra P, Jacinto M, Greenwald ES. Transient hypertension after high doses of metoclopramide. N Engl J Med . 1982:307: 1346. 63. Abe M, Orita Y, Nakashima Y, Nakamura M. Hypertensive crisis induced by metoclopramide in patient with pheochromocytoma. Angiology . 1984;35:122-128.Crossref 64. Galitzky J, Taouis M, Berlan M, Riviere D, Garrigues M, Lafontan M. α-Antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy male volunteers. Eur J Clin Invest . 1988:18: 587-594.Crossref 65. Peskind ER, Veith RC, Dorsa DM, Gumbrecht G, Raskind MA. Yohimbine increases cerebrospinal fluid and plasma norepinephrine but not arginine vasopressin in humans. Neuroendocrinology . 1989;50:286-291.Crossref 66. Murburg MM, Villacres EC, Ko GN, Veith RC. Effects of yohimbine on human sympathetic nervous system function. J Clin Endocrinol Metab . 1991;73:861-865.Crossref 67. Charney DS, Breier A, Jatlow PI, Heninger GR. Behavioral, biochemical, and blood pressure responses to alprazolam in healthy subjects: interactions with yohimbine. Psychopharmacology . 1986:88:133-140.Crossref 68. Grossman E, Rosenthal T, Peleg E, Holmes C, Goldstein DS. Oral yohimbine increases blood pressure and sympathetic nervous outflow in hypertensive patients. J Cardiovasc Pharmacol . 1993;22:22-26.Crossref 69. Grossman E, Goldstein DS, Hoffman A, Keiser HR. Glucagon and clonidine testing in the diagnosis of pheochromocytoma. Hypertension . 1991;17(pt 1):733-741.Crossref 70. Schorr RT, Rogers SN. Intraoperative cardiovascular crisis caused by glucagon. Arch Surg . 1987;122:833-834.Crossref 71. Ramoska E. Labetalol treatment of cocaine toxicity. Ann Emerg Med . 1987:16:235. 72. Silverstein W, Lenin NA, Goldfrank L. Management of the cocaine-intoxicated patient. Ann Emerg Med . 1987;16:234-235.Crossref 73. Grewal RP, Miller BL. Cocaine induced hypertensive encephalopathy. Acta Neurol . 1991;13: 279-281. 74. Flowers D, Clark JF, Westney LS. Cocaine intoxication associated with abruptio placentae. J Natl Med Assoc . 1991;83:230-232. 75. Horn PT. Persistent hypertension after prenatal cocaine exposure. J Pediatr . 1992;121:288-291.Crossref 76. Cain JW. Hypertension associated with oral administration of physostigmine in a patient with Alzheimer's disease. Am J Psychiatry . 1986; 143:910-912. 77. Gonen R, Samberg I, Sharf M. Hypertensive crisis associated with ritodrine infusion and beta-methasone administration in premature labor. Eur J Obstet Gynecol Reprod Biol . 1982;13:129-132.Crossref 78. Blackwell B. Monoamine oxidase inhibitors. Br J Psychiatry . 1986;148:216-217.Crossref 79. Lejonc JL, Gusmini D, Brochard P. Isoniazid and reaction to cheese. Ann Intern Med . 1979; 91:793. 80. Simpson GM, White K. Tyramine studies and the safety of MAOI drugs. J Clin Psychiatry . 1984; 45(pt 2):59-61. 81. Smookler S, Bermudez AJ. Hypertensive crisis resulting from an MAO inhibitor and an over-the-counter appetite suppressant. Ann Emerg Med . 1982;11:482-484.Crossref 82. Kottegoda SR. Cheese, wine and isoniazid. Lancet . 1985;2:1074.Crossref 83. Keck PE Jr, Pope HG Jr, Nierenberg AA. Autoinduction of hypertensive reactions by tranylcypromine? J Clin Psychopharmacol . 1989;9:48-51. 84. Fallon B, Foote B, Walsh BT, Roose SP. `Spontaneous' hypertensive episodes with monoamine oxidase inhibitors. J Clin Psychiatry . 1988; 49:163-165. 85. Bieck PR. Hypertensive crises with reversible inhibitors of monoamine oxidases? results of tyramine interaction studies (in German). Psychiatr Prax . 1989;16( (suppl 1) ):25-31. 86. Korn A, Da Prada M, Raffesberg W, Allen S, Gasic S. Tyramine pressor effect in man: studies with moclobemide, a novel reversible monoamine oxidase inhibitor. J Neural Transm . 1988; 26( (suppl) ):57-71. 87. Walsh BT, Hadigan CM, Wong LM. Increased pulse and blood pressure associated with desipramine treatment of bulimia nervosa. J Clin Psychopharmacol . 1992;12:163-168.Crossref 88. Louie AK, Louie EK, Lannon RA. Systemic hypertension associated with tricyclic antidepressant treatment in patients with panic disorder. Am J Cardiol . 1992;70:1306-1309.Crossref 89. Chignon JM, Lepine JP. Panic and hypertension associated with single dose of buspirone. Lancet . 1989;2:46-47.Crossref 90. Montastruc JL, Chamontin B, Senard JM, et al. Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline. Lancet . 1993:341:555.Crossref 91. Baker PB, Merigian KS, Roberts JR, Pesce AJ, Kaplan LA, Rashkin MC. Hyperthermia, hypertension, hypertonia, and coma in a massive thioridazine overdose. Am J Emerg Med . 1988;6: 346-349.Crossref 92. Hollenberg NK, Williams GH. Sodium-sensitive hypertension: implications of pathogenesis for therapy. Am J Hypertens . 1989;2:809-815.Crossref 93. Muntzel M, Drueke T. A comprehensive review of the salt and blood pressure relationship. Am J Hypertens . 1992;5(pt 1):1S-42S.Crossref 94. Gill JR Jr, Grossman E, Goldstein DS. High urinary dopa and low urinary dopamine-to-dopa ratio in salt-sensitive hypertension. Hypertension . 1991;18:614-621.Crossref 95. Rocchini AP, Key J, Bondie D, et al. The effects of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med . 1989;321:580-585.Crossref 96. Houston MC. Sodium and hypertension: a review. Arch Intern Med . 1986;146:179-185.Crossref 97. MacGregor GA, Cappuccio FP, Markandu ND. Sodium intake, high blood pressure, and calcium channel blockers. Am J Med . 1987;82: 16-22.Crossref 98. Blaustein MP. Sodium chloride, extracellular fluid volume, and hypertension. Hypertension . 1985; 7:834-835.Crossref 99. Liebman BF, Langford HG, Whitescarver SA, et al. Hypertension and sodium salts. Science . 1985; 228:351-353.Crossref 100. Michaeli J, Ben-lshay D, Kidron R, Dasberg H. Severe hypertension and lithium intoxication. JAMA . 1984;251:1680.Crossref 101. Sica DA, Harford AM, Zawada ET. Hypercalcemic hypertension in hemodialysis. Clin Nephrol . 1984;22:102-104. 102. Schwartz J. Lead, blood pressure, and cardiovascular disease in men and women. Environ Health Perspect . 1991;91:71-75.Crossref 103. Batuman V, Landy E, Maesaka JK, Wedeen RP. Contribution of lead to hypertension with renal impairment. N Engl J Med . 1983:309:17-20.Crossref 104. Hu H. A 50-year follow-up of childhood plumbism: hypertension, renal function, and hemoglobin levels among survivors. AJDC . 1991; 145:681-687. 105. Boscolo P, Carmignani M. Neurohumoral blood pressure regulation in lead exposure. Environ Health Perspect . 1988;78:101-106.Crossref 106. Engvall J, Perk J. Prevalence of hypertension among cadmium-exposed workers. Arch Environ Health . 1985;40:185-190.Crossref 107. Shigematsu I, Minowa M, Yoshida T, Miyamoto K. Recent results of health examinations on the general population in cadmiumpolluted and control areas in Japan. Environ Health Perspect . 1979;28:205-210.Crossref 108. Hermann U, Kaulich TW, Schweinsberg F. Correlation of blood pressure and cadmium and lead content of the hair in nonsmoking males (in German). Zentralbl Hyg Umweltmed . 1989;188:240-253. 109. Adamsson E, Piscator M, Nogawa K. Pulmonary and gastrointestinal exposure to cadmium oxide dust in a battery factory. Environ Health Perspect . 1979;28:219-222.Crossref 110. Porter GA. Bennett WM, Sheps SG. Cyclosporine-associated hypertension: National High Blood Pressure Education Program. Arch Intern Med . 1990;150:280-283.Crossref 111. Schorn T, Frei U, Brackmann H, et al. Cyclosporine-associated posttransplant hypertension incidence and effect on renal transplant function. Transplant Proc . 1988;20( (suppl 3) ):610-614. 112. Ponticelli C, Montagnino G, Aroldi A, Angelini C, Braga M, Tarantino A. Hypertension after renal transplantation. Am J Kidney Dis . 1993;21 ( (suppl 2) ):73-78.Crossref 113. Loughran TP Jr, Deeg HJ, Dahlberg S, Kennedy MS, Storb R, Thomas ED. Incidence of hypertension after marrow transplantation among 112 patients randomized to either cyclosporine or methotrexate as graftt disease prophylaxis. Br J Haematol . 1985;59:547-553.Crossref 114. Diaz MA, Cisneros C, Montejo JC, Garcia C, Cantalapiedra JA, Perez F. Systemic arterial hypertension in the immediate postoperative period of liver transplantation. Transplant Proc . 1989; 21:3547-3548. 115. Eid A, Perkins JD, Rakela J, Krom RA. Conversion from standard cyclosporine to low-dose cyclosporine in liver transplant recipients: effect on nephrotoxicity and hypertension beyond one year. Transplant Proc . 1989;21: 2238-2239. 116. Starling RC, Cody RJ. Cardiac transplant hypertension. Am J Cardiol . 1990;65:106-111.Crossref 117. Dieterle A, Abeywickrama K, von Graffenried B. Nephrotoxicity and hypertension in patients with autoimmune disease treated with cyclosporine. Transplant Proc . 1988;20( (suppl 4) ):349-355. 118. Deray G, Benhmida M, Le-Hoang P, et al. Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis. Ann Intern Med . 1992;117:578-583.Crossref 119. Gupta AK, Rocher LL, Schmaltz SP, et al. Short-term changes in renal function, blood pressure, and electrolyte levels in patients receiving cyclosporine for dermatologic disorders. Arch Intern Med . 1991;151:356-362.Crossref 120. de Rie MA, Meinardi MM, Bos JD. Analysis of side-effects of medium- and low-dose cyclosporin maintenance therapy in psoriasis. Br J Dermatol . 1990;123:347-353.Crossref 121. Lanese DM, Conger JD. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest . 1993;91:2144-2149.Crossref 122. Bennett WM, Porter GA. Cyclosporine-associated hypertension. Am J Med . 1988;85: 131-133.Crossref 123. Xue H, Bukoski RD, McCarron DA, Bennett WM. Induction of contraction in isolated rat aorta by cyclosporine. Transplantation . 1987;43:715-718.Crossref 124. Golub MS, Berger ME. Direct augmentation by cyclosporin A of vascular contractile response to nerve stimulation. Hypertension . 1987;9(pt 2):III96-100.Crossref 125. Murray BM, Paller MS. Beneficial effects on renal denervation and prazosin on GFR and renal blood flow after cyclosporine in rats. Clin Nephrol . 1986;25( (suppl 1) ):537-539. 126. Scherrer U, Vissing SF, Morgan BJ, et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med . 1990;323:693-699.Crossref 127. Bellet M, Cabrol C, Sassano P, Leger P, Corvol P, Menard J. Systemic hypertension after cardiac transplantation: effect of cyclosporine on renin-angiotensin-aldosterone system. Am J Cardiol . 1985;56:927-931.Crossref 128. Stern N, Lustig S, Petrasek D, et al. Cyclosporin A-induced hyperreninemic hypoaldosteronism: a model of adrenal resistance to angiotensin II. Hypertension . 1987;9(pt 2):III31-III35.Crossref 129. Murray BM, Paller MS, Ferris TF. Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int . 1985;28:767-774.Crossref 130. Barros EJ, Boim MA, Ajzen H, Ramos OL, Schor N. Glomerular hemodynamics and hormonal participation in cyclosporine nephrotoxicity. Kidney Int . 1987;32:19-25.Crossref 131. Curtis JJ, Luke RG, Jones P, Diethelm AG. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med . 1988;85:134-138.Crossref 132. Auch-Schwelk W, Bossaller C, Gotze S, Thelen J, Fleck E. Endothelial and vascular smooth muscle function after chronic treatment with cyclosporin A. J Cardiovasc Pharmacol . 1993;21:435-440.Crossref 133. Graves SW, Eder JP, Schryber SM, et al. Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantation. Clin Sci . 1989;77:501-507. 134. Muller R, Steffen HM, Brunner R, et al. Changes in the alpha adrenergic system and increase in blood pressure with recombinant human erythropoietin (rHuEpo) therapy for renal anemia. Clin Invest Med . 1991;14:614-622. 135. Levin N. Management of blood pressure changes during recombinant human erythropoietin therapy. Semin Nephrol . 1989;9( (suppl 2) ):16-20. 136. Kamata K, Marumo F, Onoyama K. Hemodynamic mechanism of the elevation in blood pressure following the improvement of anemia with recombinant human erythropoietin. Jpn Circ J . 1991;55:649-656.Crossref 137. Yamakado M, Umezu M, Nagano M, Tagawa H. Mechanisms of hypertension induced by erythropoietin in patients on hemodialysis. Clin Invest Med . 1991;14:623-629. 138. Ishimitsu T, Tsukada H, Ogawa Y, Numabe A, Yagi S. Genetic predisposition to hypertension facilitates blood pressure elevation in hemodialysis patients treated with erythropoietin. Am J Med . 1993:94:401-406.Crossref 139. Tomson CRV, Venning MC, Ward MK. Blood pressure and erythropoietin. Lancet . 1988:1: 351.Crossref 140. Brown JH, Maxwell AP, Doherty CC. Subcutaneous erythropoietin therapy and hypertensive encephalopathy. Nephrol Dial Transplant . 1990; 5:553-554.Crossref 141. Mayer G, Stefenelli T, Cada EM, Thum J, Stummvoll HK, Graf H. Blood pressure and erythropoietin. Lancet . 1988;1:351-352. 142. Martin J, Moncada S. Blood pressure, erythropoietin, and nitric oxide. Lancet . 1988;1: 644.Crossref 143. Martins Prata M, Teixeira de Sousa F, Barbas J, Vinhas J, Marques da Costa A. Arterial hypertension in patients with chronic kidney insufficiency in hemodialysis with erythropoietin (in Portuguese). Rev Port Cardiol . 1990;9:119-123. 144. Pascual J, Teruel JL, Marcen R, Liano F, Ortuno J. Blood pressure after three different forms of correction of anemia in hemodialysis. Int J Artif Organs . 1992;15:393-396. 145. Bakht FR, Kirshon B, Baker T, Cotton DB. Postpartum cardiovascular complications after bromocriptine and cocaine use. Am J Obstet Gynecol . 1990;162:1065-1066.Crossref 146. Gittelman DK. Bromocriptine associated with postpartum hypertension, seizures, and pituitary hemorrhage. Gen Hosp Psychiatry . 1991; 13:278-280.Crossref 147. Watson DL, Bhatia RK, Norman GS, Brindley BA, Sokol RJ. Bromocriptine mesylate for lactation suppression: a risk for postpartum hypertension? Obstet Gynecol . 1989;74:573-576. 148. Katz M, Kroll D, Pak I, Osimoni A, Hirsch M. Puerperal hypertension, stroke and seizures after suppression of lactation with bromocriptine. Obstet Gynecol . 1985;66:822-824. 149. Volicer L, Nelson KL. Development of reversible hypertension during disulfiram therapy. Arch Intern Med . 1984;144:1294-1296.Crossref 150. Lian C. L'alcoholism, cause d'hypertension arterielle. Bull Acad Med . 1915;74:525-528. 151. Ireland MA, Vandongen R, Davidson L, Beilin LJ, Rouse IL. Acute effects of moderate alcohol consumption on blood pressure and plasma catecholamines. Clin Sci . 1984;66:643-648. 152. Ibsen H, Christensen NJ, Rasmussen S, Hollnagel H, Damkjaer-Nielsen M, Giese J. The influence of chronic high alcohol intake on blood pressure, plasma noradrenaline concentration and plasma renin concentration. Clin Sci . 1981; 61( (suppl 7) ):377S-379S. 153. Potter JF, Beevers DG. Pressor effect of alcohol in hypertension. Lancet . 1984;1:119-122.Crossref 154. Bannan LT, Potter JF, Beevers DG, Saunders JB, Walters JR, Ingram MC. Effect of alcohol withdrawal on blood pressure, plasma renin activity, aldosterone, cortisol and dopamine beta-hydroxylase. Clin Sci . 1984;66:659-663. 155. MacMahon S. Alcohol consumption and hypertension. Hypertension . 1987;9:111-121.Crossref 156. Arkwright PD, Beilin LJ, Rouse I, Armstrong BK, Vandongen R. Effects of alcohol use and other aspects of lifestyle on blood pressure levels and prevalence of hypertension in a working population. Circulation . 1982;66:60-66.Crossref 157. Cairns V, Keil U, Kleinbaum D, Doering A, Stieber J. Alcohol consumption as a risk factor for high blood pressure: Munich Blood Pressure Study. Hypertension . 1984;6:124-131.Crossref 158. Criqui MH, Wallace RB, Mishkel M, Barrett-Connor E, Heiss G. Alcohol consumption and blood pressure: The Lipid Research Clinics Prevalence Study. Hypertension . 1981;3:557-565.Crossref 159. Gordon T, Doyle JT. Alcohol consumption and its relationship to smoking, weight, blood pressure, and blood lipids: The Albany Study. Arch Intern Med . 1986;146:262-265.Crossref 160. Gruchow HW, Sobocinski KA, Barboriak JJ. Alcohol, nutrient intake, and hypertension in US adults. JAMA . 1985;253:1567-1570.Crossref 161. Klatsky AL, Friedman GD, Armstrong MA. The relationships between alcoholic beverage use and other traits to blood pressure: a new Kaiser Permanente study. Circulation . 1986:73: 628-636.Crossref 162. Klatsky AL, Friedman GD, Siegelaud AB, Gerard MJ. Alcohol consumption and blood pressure: Kaiser-Permanente Multiphasic Health Examination data. N Engl J Med . 1977;296:1194-1200.Crossref 163. MacMahon SW, Blachet KRB, MacDonald GJ. Obesity, alcohol consumption and blood pressure in Australian men and women: The Natural Heart Foundation of Australia Risk Factor Prevalence Study. J Hypertension . 1984;2:85-91.Crossref 164. Yamada Y, Ishizaki M, Kido T, et al. Alcohol, high blood pressure, and serum gammaglutamyl transpeptidase level. Hypertension . 1991;18:819-826.Crossref 165. Baer L, Rudichevich I. Cigarette smoking in hypertensive patients: blood pressure and endocrine responses. Am J Med . 1985;78:564-568.Crossref 166. Cryer PE, Haymond MW, Santiago JV, Shah SD. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med . 1976;295:573-577.Crossref 167. Blachley JD, Knochel JP. Tobacco chewer's hypokalemia: licorice revisited. N Engl J Med . 1980; 302:784-785.Crossref 168. Wells DG, Rustick JM. Hypertension from smokeless tobacco. Anesthesiology . 1986:65:339.Crossref 169. Easton PA, Koval A. Hypertensive reaction with sulindac. Can Med Assoc J . 1980;122:1273-1274. 170. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med . 1993;153:477-484.Crossref 171. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? a meta-analysis. Arch Intern Med . 1994; 121:289-300. 172. Hamilton BP, Mersey JH, Hamilton J, Kuzbida G, Pavlis R, Levinson P. Withdrawal phenomenon in subjects with essential hypertension on clonidine or triamenidine. Clin Pharmacol Ther . 1984;36:628-633.Crossref 173. Hui KK. Hypertensive crisis induced by interaction of clonidine with imipramine. JAm Geriatr Soc . 1983;31:164-165. 174. Mehta JL, Lopez LM. Rebound hypertension following abrupt cessation of clonidine and metoprolol treatment with labetalol. Arch Intern Med . 1987;147:389-390.Crossref 175. Metz S, Klein C, Morton N. Rebound hypertension after discontinuation of transdermal clonidine therapy. Am J Med . 1987;82:17-19.Crossref 176. Stiff JL, Harris DB. Clonidine withdrawal complicated by amitriptyline therapy. Anesthesiology . 1983;59:73-74.Crossref 177. Makker SP, Moorthy B. Rebound hypertension following minoxidil withdrawal. J Pediatr . 1980; 96:762-766.Crossref 178. Bursztyn M, Tordjman K, Grossman E, Rosenthal T. Hypertensive crisis associated with nifedipine withdrawal. Arch Intern Med . 1986; 146:397.Crossref 179. Webb DB, White JP. Hypertension after taking hydralazine. BMJ . 1980:280:1582.Crossref 180. Young E, Levey BA, Shapiro AP. Paradoxical hypertension from clonidine. Ann Intern Med . 1984;101:282-283.Crossref 181. Yagupsky P, Gorodischer R. Massive clonidine ingestion with hypertension in a 9-month-old infant. Pediatrics . 1983;72:500-502. 182. Dire DJ, Kuhns DW. The use of sublingual nifedipine in a patient with clonidine overdose. J Emerg Med . 1988;6:125-128.Crossref 183. Veber B, Gauthe M, Michel-Cherqui M, des Mesnards V, Fischler M. Severe hypertension during postpartum haemorrhage after IV administration of prostaglandin E2. Br J Anaesth . 1992;68:623-624.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

High Blood Pressure: A Side Effect of Drugs, Poisons, and Food

Loading next page...
 
/lp/american-medical-association/high-blood-pressure-a-side-effect-of-drugs-poisons-and-food-zdntR0vL49
Publisher
American Medical Association
Copyright
Copyright © 1995 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinte.1995.00430050022003
Publisher site
See Article on Publisher Site

Abstract

Abstract A variety of therapeutic agents or chemical substances can induce either a transient or a sustained increase in blood pressure. These agents increase arterial pressure by either causing sodium retention and extracellular volume expansion or directly or indirectly activating the sympathetic nervous system. Some agents act directly on arteriolar smooth muscle. For certain agents, the mechanism of pressure elevation is mixed or unknown. Paradoxically, some agents that are used to lower arterial pressure may acutely increase arterial pressure. Also, a rebound increase in pressure may be encountered after discontinuation of certain antihypertensive agents. In general, these chemically induced increases in arterial pressure are small and transient; however, severe hypertension involving encephalopathy, stroke, and irreversible renal failure has been reported. Careful evaluation of a patient's drug regimen may identify chemically induced hypertension and prevent the need for evaluation and therapy. This study reviews the therapeutic agents or chemical substances that elevate blood pressure and their mechanisms of action. (Arch Intern Med. 1995;155:450-460) References 1. Messerli FH, Frohlich ED. High blood pressure: a common side effect of drugs, poisons and foods. Arch Intern Med . 1979;139:682-687.Crossref 2. Oren S, Grossman E, Messerli FH, Frohlich ED. High blood pressure: side effects of drugs, poisons, and food. Cardiol Clin . 1988;6:467-474. 3. Whitworth JA. Adrenocorticotrophin and steroid-induced hypertension in humans. Kidney Int . 1992;37( (suppl) ):34-37. 4. Whiteworth JA. Mechanisms of glucocorticoidinduced hypertension. Kidney Int . 1987;31: 1213-1224.Crossref 5. Sudhir K, Jennings GL, Esler MD, et al. Hydrocortisone-induced hypertension in humans: pressor responsiveness and sympathetic function. Hypertension . 1989:13:416-421.Crossref 6. Scoggins BA, Coghlan JP, Denton DA, et al. How do adrenocortical steroid hormones produce hypertension? Clin Exp Hypertens . 1984;6:315-328.Crossref 7. Whitworth JA, Gordon D, Andrews J, Scoggins BA. The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. J Hypertens . 1989;7:537-549.Crossref 8. Coghlan JP, Reid AF, Spence CD, Scoggins BA, Whitworth JA. Receptors and steroid-dependent hypertension. Clin Exp Pharmacol Physiol . 1988;15:163-172.Crossref 9. Sanders BP, Portman RJ, Ramey RA, Hill M, Strunk RC. Hypertension during reduction of long-term steroid therapy in young subjects with asthma. J Allergy Clin Immunol . 1992;89:816-821.Crossref 10. Beretta-Picolli C, Salvadore G, Crivelli GSPL, Weidmann P. Body-sodium and blood volume in a patient with licorice-induced hypertension. J Hypertens . 1985:3:19-23.Crossref 11. Horn B. Raritäten in der hausärztlichen praxis: Folgerungen für die aus- und weiterbildung (Rarities in the General Practice). Schweiz Rundsch Med Prax . 1986;75:1323-1327. 12. Leal-Cerro A, Garcia-Luna PP, Villar J, et al. Arterial hypertension as a complication of prolonged ketoconazole treatment. J Hypertens . 1989;7( (suppl) ):S212-213.Crossref 13. Marin F, Gonzalez Quintela A, Moya M, Suarez E, de Zarraga M. Pseudohyperaldosteronism due to application of an antihemorrhoid cream. Nephron . 1989:52:281-282.Crossref 14. Bartorelli A, Rimondini A. Severe hypertension in childhood due to prolonged skin application of a mineralocorticoid ointment. Hypertension . 1984:6:586-588.Crossref 15. Mantero F, Armanini D, Opocher G, et al. Mineralocorticoid hypertension due to a nasal spray containing 9 α-fluoroprednisolone. Am J Med . 1981;71:352-357.Crossref 16. Woods JW. Oral contraceptives and hypertension. Hypertension . 1988;11( (3) pt 2):11-15.Crossref 17. Tyson JE. Oral contraception and elevated blood pressure. Am Obstet Gynecol . 1968;100:875-877. 18. Saruta T. Saade GA, Kaplan NM. A possible mechanism for hypertension induced by oral contraceptives: diminished feedback suppression of renin release. Arch Intern Med . 1970;126:621-626.Crossref 19. Clezy TM, Foy BN, Hodge RL, Lumbers ER. Oral contraceptives and hypertension: an epidemiological survey. Br Heart J . 1972;34:1238-1243.Crossref 20. Khaw KT, Peart WS. Blood pressure and contraceptive use. BMJ . 1982;285:403-407.Crossref 21. Kannel WB. Oral contraceptive hypertension and thromboembolism. Int J Gynaecol Obstet . 1978-1979;16:466-472. 22. Mashchak CA, Lobo RA. Estrogen replacement therapy and hypertension. J Reprod Med . 1985;30:805-810. 23. Okada Y, Ogihara T. Hyperreninemia and hypertension observed during Kaufmann therapy of patients with gonadal dysgenesis and hypopituitarism. Endocrinol Jpn . 1989;36:211-218.Crossref 24. Gembitskii EV, Portnoi AS, Begunov AV. Diagnosis and therapeutic correction of changes in the cardiovascular system of patients with prostatic cancer treated with estrogens. Klin Med Mosk . 1990;68:41-45. 25. Graham S, Kennedy M. Recent developments in the toxicology of anabolic steroids. Drug Safety . 1990;5:458-476.Crossref 26. Bretza JA, Novey HS, Vaziri ND, Warner AS. Hypertension: a complication of danazol therapy. Arch Intern Med . 1980;140:1379-1380.Crossref 27. El-Din AS, Mostafa SM. Severe hypertension during anaesthesia for dacryocystorhinostomy. Anaesthesia . 1985;40:787-789.Crossref 28. Broughton Pipkin F, Waldron BA. Ketamine hypertension and the renin-angiotensin system. Clin Exp Hypertens . 1983;5:875-883.Crossref 29. Murphy JL Jr. Hypertension and pulmonary oedema associated with ketamine administration in a patient with a history of substance abuse. Can J Anaesth . 1993;40:160-164.Crossref 30. Munro HM, Sleigh JW, Paxton LD. The cardiovascular response to ketamine: the effects of clonidine and lignocaine. Acta Anaesthesiol Scand . 1993;37:75-78.Crossref 31. Mark JB, Greenberg LM. Intraoperative awareness and hypertensive crisis during high-dose fentanyl-diazepam-oxygen anesthesia. Anesth Analg . 1983;62:698-700.Crossref 32. Kashtan HI, Heyneker TJ, Morell RC. Atypical response to scopolamine in a patient with type IV hereditary sensory and autonomic neuropathy. Anesthesiology . 1992;76:140-142.Crossref 33. Wasserberger J, Ordog GJ. Naloxone-induced hypertension in patients on clonidine. Ann Emerg Med . 1988:17:557.Crossref 34. Levin ER, Sharp B, Drayer Jl, Weber MA. Case report: severe hypertension induced by naloxone. Med Sci . 1985:290:70-72.Crossref 35. Reinhart S. An acute hypertensive response after intravenous use of a new pentazocine formulation. Ann Emerg Med . 1985;14:591-593.Crossref 36. Saken R, Kates GL, Miller K. Drug-induced hypertension in infancy. J Pediatr . 1979;95:1077-1079.Crossref 37. Wellwood M, Goresky GV. Systemic hypertension associated with topical administration of 2.5% phenylephrine HCI. Am J Ophthalmol . 1982; 93:369-370. 38. Lai YK. Adverse effect of intraoperative phenylephrine 10%: case report. Br J Ophthalmol . 1989;73:468-469.Crossref 39. Nelson ME, Andrzejowski AZ. Systemic hypertension in patients receiving dipivalyl adrenaline for glaucoma. BMJ . 1988:297:741-742.Crossref 40. Whelan TV. Propranolol, epinephrine, and accelerated hypertension during hemodialysis. Ann Intern Med . 1987;106:327.Crossref 41. Brummett RE. Warning to otolaryngologists using local anesthetics containing epinephrine. Acta Otolaryngol . 1984:110:561. 42. Mito RS, Yagiela JA. Hypertensive response to levonordefrin in a patient receiving propranolol: report of case. J Am Dent Assoc . 1988;116:55-57. 43. Mann SJ, Krakoff LR. Hypertensive crisis caused by hypoglycemia and propranolol. Arch Intern Med . 1984;144:2427-2428.Crossref 44. Ryan JR, La Corte W, Jain A, McMahon FG. Hypertension in hypoglycemic diabetes treated with beta adrenergic antagonists. Hypertension . 1985;7:443-446. 45. Pentel P. Toxicity of over-the-counter stimulants. JAMA . 1984;252:1898-1903.Crossref 46. Heyman SN, Mevorach D, Ghanem J. Hypertensive crisis from chronic intoxication with nasal decongestant and cough medications. DICP . 1991;25:1068-1070. 47. Mariani PJ. Pseudoephedrine-induced hypertensive emergency: treatment with labetalol. Am J Emerg Med . 1986;4:141-142.Crossref 48. Bernstein E, Diskant BM. Phenylpropanolamine: a potentially hazardous drug. Ann Emerg Med . 1982;11:311-315.Crossref 49. Howrie DL, Wolfson JH. Phenylpropanolamineinduced hypertensive seizures. J Pediatr . 1983; 102:143-145.Crossref 50. Lasange L. Phenylpropanolamine and blood pressure. JAMA . 1985;253:2491-2492.Crossref 51. Pentel PR, Asinger RW, Benowitz NL. Propranolol antagonism of phenylpropanolamine-induced hypertension. Clin Pharmacol Ther . 1985: 37:488-494.Crossref 52. Horowitz JD, Lang WJ, Howes LG, et al. Hypertensive responses induced by phenylpropanolamine in anorectic and decongestant preparations. Lancet . 1980;1:60-61.Crossref 53. Lake CR, Zaloga G, Clymer R, Quirk RM, Chernow B. A double dose of phenylpropanolamine causes transient hypertension. Am J Med . 1988;85:339-343.Crossref 54. Lake CR, Zaloga G, Bray J, Rosenberg D, Chernow B. Transient hypertension after two phenylpropanolamine diet aids and the effects of caffeine: a placebo-controlled follow-up study. Am J Med . 1989:86:427-432.Crossref 55. Morgan JP, Funderburk FR. Phenylpropanolamine and blood pressure: a review of prospective studies. Am J Clin Nutr . 1992;55 ( (suppl 1) ):206S-210S. 56. Lovallo WR, Pincomb GA, Sung BH, Everson SA, Passey RB, Wilson MF. Hypertension risk and caffeine's effect on cardiovascular activity during mental stress in young men. Health Psychol . 1991;10:236-243.Crossref 57. James JE. The influence of user status and anxious disposition on the hypertensive effects of caffeine. Int J Psychophysiol . 1990;10:171-179.Crossref 58. Greenstadt L, Yang L, Shapiro D. Caffeine, mental stress, and risk for hypertension: a crosscultural replication. Psychosom Med . 1988;50:15-22.Crossref 59. Acevedo AG, Smith JK. Adverse reaction to use of caffeine in ECT. Am J Psychiatry . 1988;145: 529-530. 60. Harrison WM. McGrath PJ, Stewart JW, Quitkin F. MAOIs and hypertensive crises: the role of OTC drugs. J Clin Psychiatry . 1989;50:64-65. 61. Roche H, Hyman G, Nahas G. Hypertension and intravenous antidopaminergic drugs. N Engl J Med . 1985;312:1125-1126.Crossref 62. Sheridan C, Chandra P, Jacinto M, Greenwald ES. Transient hypertension after high doses of metoclopramide. N Engl J Med . 1982:307: 1346. 63. Abe M, Orita Y, Nakashima Y, Nakamura M. Hypertensive crisis induced by metoclopramide in patient with pheochromocytoma. Angiology . 1984;35:122-128.Crossref 64. Galitzky J, Taouis M, Berlan M, Riviere D, Garrigues M, Lafontan M. α-Antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy male volunteers. Eur J Clin Invest . 1988:18: 587-594.Crossref 65. Peskind ER, Veith RC, Dorsa DM, Gumbrecht G, Raskind MA. Yohimbine increases cerebrospinal fluid and plasma norepinephrine but not arginine vasopressin in humans. Neuroendocrinology . 1989;50:286-291.Crossref 66. Murburg MM, Villacres EC, Ko GN, Veith RC. Effects of yohimbine on human sympathetic nervous system function. J Clin Endocrinol Metab . 1991;73:861-865.Crossref 67. Charney DS, Breier A, Jatlow PI, Heninger GR. Behavioral, biochemical, and blood pressure responses to alprazolam in healthy subjects: interactions with yohimbine. Psychopharmacology . 1986:88:133-140.Crossref 68. Grossman E, Rosenthal T, Peleg E, Holmes C, Goldstein DS. Oral yohimbine increases blood pressure and sympathetic nervous outflow in hypertensive patients. J Cardiovasc Pharmacol . 1993;22:22-26.Crossref 69. Grossman E, Goldstein DS, Hoffman A, Keiser HR. Glucagon and clonidine testing in the diagnosis of pheochromocytoma. Hypertension . 1991;17(pt 1):733-741.Crossref 70. Schorr RT, Rogers SN. Intraoperative cardiovascular crisis caused by glucagon. Arch Surg . 1987;122:833-834.Crossref 71. Ramoska E. Labetalol treatment of cocaine toxicity. Ann Emerg Med . 1987:16:235. 72. Silverstein W, Lenin NA, Goldfrank L. Management of the cocaine-intoxicated patient. Ann Emerg Med . 1987;16:234-235.Crossref 73. Grewal RP, Miller BL. Cocaine induced hypertensive encephalopathy. Acta Neurol . 1991;13: 279-281. 74. Flowers D, Clark JF, Westney LS. Cocaine intoxication associated with abruptio placentae. J Natl Med Assoc . 1991;83:230-232. 75. Horn PT. Persistent hypertension after prenatal cocaine exposure. J Pediatr . 1992;121:288-291.Crossref 76. Cain JW. Hypertension associated with oral administration of physostigmine in a patient with Alzheimer's disease. Am J Psychiatry . 1986; 143:910-912. 77. Gonen R, Samberg I, Sharf M. Hypertensive crisis associated with ritodrine infusion and beta-methasone administration in premature labor. Eur J Obstet Gynecol Reprod Biol . 1982;13:129-132.Crossref 78. Blackwell B. Monoamine oxidase inhibitors. Br J Psychiatry . 1986;148:216-217.Crossref 79. Lejonc JL, Gusmini D, Brochard P. Isoniazid and reaction to cheese. Ann Intern Med . 1979; 91:793. 80. Simpson GM, White K. Tyramine studies and the safety of MAOI drugs. J Clin Psychiatry . 1984; 45(pt 2):59-61. 81. Smookler S, Bermudez AJ. Hypertensive crisis resulting from an MAO inhibitor and an over-the-counter appetite suppressant. Ann Emerg Med . 1982;11:482-484.Crossref 82. Kottegoda SR. Cheese, wine and isoniazid. Lancet . 1985;2:1074.Crossref 83. Keck PE Jr, Pope HG Jr, Nierenberg AA. Autoinduction of hypertensive reactions by tranylcypromine? J Clin Psychopharmacol . 1989;9:48-51. 84. Fallon B, Foote B, Walsh BT, Roose SP. `Spontaneous' hypertensive episodes with monoamine oxidase inhibitors. J Clin Psychiatry . 1988; 49:163-165. 85. Bieck PR. Hypertensive crises with reversible inhibitors of monoamine oxidases? results of tyramine interaction studies (in German). Psychiatr Prax . 1989;16( (suppl 1) ):25-31. 86. Korn A, Da Prada M, Raffesberg W, Allen S, Gasic S. Tyramine pressor effect in man: studies with moclobemide, a novel reversible monoamine oxidase inhibitor. J Neural Transm . 1988; 26( (suppl) ):57-71. 87. Walsh BT, Hadigan CM, Wong LM. Increased pulse and blood pressure associated with desipramine treatment of bulimia nervosa. J Clin Psychopharmacol . 1992;12:163-168.Crossref 88. Louie AK, Louie EK, Lannon RA. Systemic hypertension associated with tricyclic antidepressant treatment in patients with panic disorder. Am J Cardiol . 1992;70:1306-1309.Crossref 89. Chignon JM, Lepine JP. Panic and hypertension associated with single dose of buspirone. Lancet . 1989;2:46-47.Crossref 90. Montastruc JL, Chamontin B, Senard JM, et al. Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline. Lancet . 1993:341:555.Crossref 91. Baker PB, Merigian KS, Roberts JR, Pesce AJ, Kaplan LA, Rashkin MC. Hyperthermia, hypertension, hypertonia, and coma in a massive thioridazine overdose. Am J Emerg Med . 1988;6: 346-349.Crossref 92. Hollenberg NK, Williams GH. Sodium-sensitive hypertension: implications of pathogenesis for therapy. Am J Hypertens . 1989;2:809-815.Crossref 93. Muntzel M, Drueke T. A comprehensive review of the salt and blood pressure relationship. Am J Hypertens . 1992;5(pt 1):1S-42S.Crossref 94. Gill JR Jr, Grossman E, Goldstein DS. High urinary dopa and low urinary dopamine-to-dopa ratio in salt-sensitive hypertension. Hypertension . 1991;18:614-621.Crossref 95. Rocchini AP, Key J, Bondie D, et al. The effects of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med . 1989;321:580-585.Crossref 96. Houston MC. Sodium and hypertension: a review. Arch Intern Med . 1986;146:179-185.Crossref 97. MacGregor GA, Cappuccio FP, Markandu ND. Sodium intake, high blood pressure, and calcium channel blockers. Am J Med . 1987;82: 16-22.Crossref 98. Blaustein MP. Sodium chloride, extracellular fluid volume, and hypertension. Hypertension . 1985; 7:834-835.Crossref 99. Liebman BF, Langford HG, Whitescarver SA, et al. Hypertension and sodium salts. Science . 1985; 228:351-353.Crossref 100. Michaeli J, Ben-lshay D, Kidron R, Dasberg H. Severe hypertension and lithium intoxication. JAMA . 1984;251:1680.Crossref 101. Sica DA, Harford AM, Zawada ET. Hypercalcemic hypertension in hemodialysis. Clin Nephrol . 1984;22:102-104. 102. Schwartz J. Lead, blood pressure, and cardiovascular disease in men and women. Environ Health Perspect . 1991;91:71-75.Crossref 103. Batuman V, Landy E, Maesaka JK, Wedeen RP. Contribution of lead to hypertension with renal impairment. N Engl J Med . 1983:309:17-20.Crossref 104. Hu H. A 50-year follow-up of childhood plumbism: hypertension, renal function, and hemoglobin levels among survivors. AJDC . 1991; 145:681-687. 105. Boscolo P, Carmignani M. Neurohumoral blood pressure regulation in lead exposure. Environ Health Perspect . 1988;78:101-106.Crossref 106. Engvall J, Perk J. Prevalence of hypertension among cadmium-exposed workers. Arch Environ Health . 1985;40:185-190.Crossref 107. Shigematsu I, Minowa M, Yoshida T, Miyamoto K. Recent results of health examinations on the general population in cadmiumpolluted and control areas in Japan. Environ Health Perspect . 1979;28:205-210.Crossref 108. Hermann U, Kaulich TW, Schweinsberg F. Correlation of blood pressure and cadmium and lead content of the hair in nonsmoking males (in German). Zentralbl Hyg Umweltmed . 1989;188:240-253. 109. Adamsson E, Piscator M, Nogawa K. Pulmonary and gastrointestinal exposure to cadmium oxide dust in a battery factory. Environ Health Perspect . 1979;28:219-222.Crossref 110. Porter GA. Bennett WM, Sheps SG. Cyclosporine-associated hypertension: National High Blood Pressure Education Program. Arch Intern Med . 1990;150:280-283.Crossref 111. Schorn T, Frei U, Brackmann H, et al. Cyclosporine-associated posttransplant hypertension incidence and effect on renal transplant function. Transplant Proc . 1988;20( (suppl 3) ):610-614. 112. Ponticelli C, Montagnino G, Aroldi A, Angelini C, Braga M, Tarantino A. Hypertension after renal transplantation. Am J Kidney Dis . 1993;21 ( (suppl 2) ):73-78.Crossref 113. Loughran TP Jr, Deeg HJ, Dahlberg S, Kennedy MS, Storb R, Thomas ED. Incidence of hypertension after marrow transplantation among 112 patients randomized to either cyclosporine or methotrexate as graftt disease prophylaxis. Br J Haematol . 1985;59:547-553.Crossref 114. Diaz MA, Cisneros C, Montejo JC, Garcia C, Cantalapiedra JA, Perez F. Systemic arterial hypertension in the immediate postoperative period of liver transplantation. Transplant Proc . 1989; 21:3547-3548. 115. Eid A, Perkins JD, Rakela J, Krom RA. Conversion from standard cyclosporine to low-dose cyclosporine in liver transplant recipients: effect on nephrotoxicity and hypertension beyond one year. Transplant Proc . 1989;21: 2238-2239. 116. Starling RC, Cody RJ. Cardiac transplant hypertension. Am J Cardiol . 1990;65:106-111.Crossref 117. Dieterle A, Abeywickrama K, von Graffenried B. Nephrotoxicity and hypertension in patients with autoimmune disease treated with cyclosporine. Transplant Proc . 1988;20( (suppl 4) ):349-355. 118. Deray G, Benhmida M, Le-Hoang P, et al. Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis. Ann Intern Med . 1992;117:578-583.Crossref 119. Gupta AK, Rocher LL, Schmaltz SP, et al. Short-term changes in renal function, blood pressure, and electrolyte levels in patients receiving cyclosporine for dermatologic disorders. Arch Intern Med . 1991;151:356-362.Crossref 120. de Rie MA, Meinardi MM, Bos JD. Analysis of side-effects of medium- and low-dose cyclosporin maintenance therapy in psoriasis. Br J Dermatol . 1990;123:347-353.Crossref 121. Lanese DM, Conger JD. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest . 1993;91:2144-2149.Crossref 122. Bennett WM, Porter GA. Cyclosporine-associated hypertension. Am J Med . 1988;85: 131-133.Crossref 123. Xue H, Bukoski RD, McCarron DA, Bennett WM. Induction of contraction in isolated rat aorta by cyclosporine. Transplantation . 1987;43:715-718.Crossref 124. Golub MS, Berger ME. Direct augmentation by cyclosporin A of vascular contractile response to nerve stimulation. Hypertension . 1987;9(pt 2):III96-100.Crossref 125. Murray BM, Paller MS. Beneficial effects on renal denervation and prazosin on GFR and renal blood flow after cyclosporine in rats. Clin Nephrol . 1986;25( (suppl 1) ):537-539. 126. Scherrer U, Vissing SF, Morgan BJ, et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med . 1990;323:693-699.Crossref 127. Bellet M, Cabrol C, Sassano P, Leger P, Corvol P, Menard J. Systemic hypertension after cardiac transplantation: effect of cyclosporine on renin-angiotensin-aldosterone system. Am J Cardiol . 1985;56:927-931.Crossref 128. Stern N, Lustig S, Petrasek D, et al. Cyclosporin A-induced hyperreninemic hypoaldosteronism: a model of adrenal resistance to angiotensin II. Hypertension . 1987;9(pt 2):III31-III35.Crossref 129. Murray BM, Paller MS, Ferris TF. Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int . 1985;28:767-774.Crossref 130. Barros EJ, Boim MA, Ajzen H, Ramos OL, Schor N. Glomerular hemodynamics and hormonal participation in cyclosporine nephrotoxicity. Kidney Int . 1987;32:19-25.Crossref 131. Curtis JJ, Luke RG, Jones P, Diethelm AG. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med . 1988;85:134-138.Crossref 132. Auch-Schwelk W, Bossaller C, Gotze S, Thelen J, Fleck E. Endothelial and vascular smooth muscle function after chronic treatment with cyclosporin A. J Cardiovasc Pharmacol . 1993;21:435-440.Crossref 133. Graves SW, Eder JP, Schryber SM, et al. Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantation. Clin Sci . 1989;77:501-507. 134. Muller R, Steffen HM, Brunner R, et al. Changes in the alpha adrenergic system and increase in blood pressure with recombinant human erythropoietin (rHuEpo) therapy for renal anemia. Clin Invest Med . 1991;14:614-622. 135. Levin N. Management of blood pressure changes during recombinant human erythropoietin therapy. Semin Nephrol . 1989;9( (suppl 2) ):16-20. 136. Kamata K, Marumo F, Onoyama K. Hemodynamic mechanism of the elevation in blood pressure following the improvement of anemia with recombinant human erythropoietin. Jpn Circ J . 1991;55:649-656.Crossref 137. Yamakado M, Umezu M, Nagano M, Tagawa H. Mechanisms of hypertension induced by erythropoietin in patients on hemodialysis. Clin Invest Med . 1991;14:623-629. 138. Ishimitsu T, Tsukada H, Ogawa Y, Numabe A, Yagi S. Genetic predisposition to hypertension facilitates blood pressure elevation in hemodialysis patients treated with erythropoietin. Am J Med . 1993:94:401-406.Crossref 139. Tomson CRV, Venning MC, Ward MK. Blood pressure and erythropoietin. Lancet . 1988:1: 351.Crossref 140. Brown JH, Maxwell AP, Doherty CC. Subcutaneous erythropoietin therapy and hypertensive encephalopathy. Nephrol Dial Transplant . 1990; 5:553-554.Crossref 141. Mayer G, Stefenelli T, Cada EM, Thum J, Stummvoll HK, Graf H. Blood pressure and erythropoietin. Lancet . 1988;1:351-352. 142. Martin J, Moncada S. Blood pressure, erythropoietin, and nitric oxide. Lancet . 1988;1: 644.Crossref 143. Martins Prata M, Teixeira de Sousa F, Barbas J, Vinhas J, Marques da Costa A. Arterial hypertension in patients with chronic kidney insufficiency in hemodialysis with erythropoietin (in Portuguese). Rev Port Cardiol . 1990;9:119-123. 144. Pascual J, Teruel JL, Marcen R, Liano F, Ortuno J. Blood pressure after three different forms of correction of anemia in hemodialysis. Int J Artif Organs . 1992;15:393-396. 145. Bakht FR, Kirshon B, Baker T, Cotton DB. Postpartum cardiovascular complications after bromocriptine and cocaine use. Am J Obstet Gynecol . 1990;162:1065-1066.Crossref 146. Gittelman DK. Bromocriptine associated with postpartum hypertension, seizures, and pituitary hemorrhage. Gen Hosp Psychiatry . 1991; 13:278-280.Crossref 147. Watson DL, Bhatia RK, Norman GS, Brindley BA, Sokol RJ. Bromocriptine mesylate for lactation suppression: a risk for postpartum hypertension? Obstet Gynecol . 1989;74:573-576. 148. Katz M, Kroll D, Pak I, Osimoni A, Hirsch M. Puerperal hypertension, stroke and seizures after suppression of lactation with bromocriptine. Obstet Gynecol . 1985;66:822-824. 149. Volicer L, Nelson KL. Development of reversible hypertension during disulfiram therapy. Arch Intern Med . 1984;144:1294-1296.Crossref 150. Lian C. L'alcoholism, cause d'hypertension arterielle. Bull Acad Med . 1915;74:525-528. 151. Ireland MA, Vandongen R, Davidson L, Beilin LJ, Rouse IL. Acute effects of moderate alcohol consumption on blood pressure and plasma catecholamines. Clin Sci . 1984;66:643-648. 152. Ibsen H, Christensen NJ, Rasmussen S, Hollnagel H, Damkjaer-Nielsen M, Giese J. The influence of chronic high alcohol intake on blood pressure, plasma noradrenaline concentration and plasma renin concentration. Clin Sci . 1981; 61( (suppl 7) ):377S-379S. 153. Potter JF, Beevers DG. Pressor effect of alcohol in hypertension. Lancet . 1984;1:119-122.Crossref 154. Bannan LT, Potter JF, Beevers DG, Saunders JB, Walters JR, Ingram MC. Effect of alcohol withdrawal on blood pressure, plasma renin activity, aldosterone, cortisol and dopamine beta-hydroxylase. Clin Sci . 1984;66:659-663. 155. MacMahon S. Alcohol consumption and hypertension. Hypertension . 1987;9:111-121.Crossref 156. Arkwright PD, Beilin LJ, Rouse I, Armstrong BK, Vandongen R. Effects of alcohol use and other aspects of lifestyle on blood pressure levels and prevalence of hypertension in a working population. Circulation . 1982;66:60-66.Crossref 157. Cairns V, Keil U, Kleinbaum D, Doering A, Stieber J. Alcohol consumption as a risk factor for high blood pressure: Munich Blood Pressure Study. Hypertension . 1984;6:124-131.Crossref 158. Criqui MH, Wallace RB, Mishkel M, Barrett-Connor E, Heiss G. Alcohol consumption and blood pressure: The Lipid Research Clinics Prevalence Study. Hypertension . 1981;3:557-565.Crossref 159. Gordon T, Doyle JT. Alcohol consumption and its relationship to smoking, weight, blood pressure, and blood lipids: The Albany Study. Arch Intern Med . 1986;146:262-265.Crossref 160. Gruchow HW, Sobocinski KA, Barboriak JJ. Alcohol, nutrient intake, and hypertension in US adults. JAMA . 1985;253:1567-1570.Crossref 161. Klatsky AL, Friedman GD, Armstrong MA. The relationships between alcoholic beverage use and other traits to blood pressure: a new Kaiser Permanente study. Circulation . 1986:73: 628-636.Crossref 162. Klatsky AL, Friedman GD, Siegelaud AB, Gerard MJ. Alcohol consumption and blood pressure: Kaiser-Permanente Multiphasic Health Examination data. N Engl J Med . 1977;296:1194-1200.Crossref 163. MacMahon SW, Blachet KRB, MacDonald GJ. Obesity, alcohol consumption and blood pressure in Australian men and women: The Natural Heart Foundation of Australia Risk Factor Prevalence Study. J Hypertension . 1984;2:85-91.Crossref 164. Yamada Y, Ishizaki M, Kido T, et al. Alcohol, high blood pressure, and serum gammaglutamyl transpeptidase level. Hypertension . 1991;18:819-826.Crossref 165. Baer L, Rudichevich I. Cigarette smoking in hypertensive patients: blood pressure and endocrine responses. Am J Med . 1985;78:564-568.Crossref 166. Cryer PE, Haymond MW, Santiago JV, Shah SD. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med . 1976;295:573-577.Crossref 167. Blachley JD, Knochel JP. Tobacco chewer's hypokalemia: licorice revisited. N Engl J Med . 1980; 302:784-785.Crossref 168. Wells DG, Rustick JM. Hypertension from smokeless tobacco. Anesthesiology . 1986:65:339.Crossref 169. Easton PA, Koval A. Hypertensive reaction with sulindac. Can Med Assoc J . 1980;122:1273-1274. 170. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med . 1993;153:477-484.Crossref 171. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? a meta-analysis. Arch Intern Med . 1994; 121:289-300. 172. Hamilton BP, Mersey JH, Hamilton J, Kuzbida G, Pavlis R, Levinson P. Withdrawal phenomenon in subjects with essential hypertension on clonidine or triamenidine. Clin Pharmacol Ther . 1984;36:628-633.Crossref 173. Hui KK. Hypertensive crisis induced by interaction of clonidine with imipramine. JAm Geriatr Soc . 1983;31:164-165. 174. Mehta JL, Lopez LM. Rebound hypertension following abrupt cessation of clonidine and metoprolol treatment with labetalol. Arch Intern Med . 1987;147:389-390.Crossref 175. Metz S, Klein C, Morton N. Rebound hypertension after discontinuation of transdermal clonidine therapy. Am J Med . 1987;82:17-19.Crossref 176. Stiff JL, Harris DB. Clonidine withdrawal complicated by amitriptyline therapy. Anesthesiology . 1983;59:73-74.Crossref 177. Makker SP, Moorthy B. Rebound hypertension following minoxidil withdrawal. J Pediatr . 1980; 96:762-766.Crossref 178. Bursztyn M, Tordjman K, Grossman E, Rosenthal T. Hypertensive crisis associated with nifedipine withdrawal. Arch Intern Med . 1986; 146:397.Crossref 179. Webb DB, White JP. Hypertension after taking hydralazine. BMJ . 1980:280:1582.Crossref 180. Young E, Levey BA, Shapiro AP. Paradoxical hypertension from clonidine. Ann Intern Med . 1984;101:282-283.Crossref 181. Yagupsky P, Gorodischer R. Massive clonidine ingestion with hypertension in a 9-month-old infant. Pediatrics . 1983;72:500-502. 182. Dire DJ, Kuhns DW. The use of sublingual nifedipine in a patient with clonidine overdose. J Emerg Med . 1988;6:125-128.Crossref 183. Veber B, Gauthe M, Michel-Cherqui M, des Mesnards V, Fischler M. Severe hypertension during postpartum haemorrhage after IV administration of prostaglandin E2. Br J Anaesth . 1992;68:623-624.Crossref

Journal

Archives of Internal MedicineAmerican Medical Association

Published: Mar 13, 1995

References